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ABSTRACT
Administration of drugs of abuse induces strong molecular 
adaptations and plasticity within the mesolimbic dopamine (DA) 
system, a pathway essential for reward-seeking behavior. Little is 
known about the specific targets involved in this neuroadaptation 
process, but there are indications that cocaine and other drugs of 
abuse share the ability to alter the morphology of neuronal dendrites 
and spines, the primary site of excitatory synapses in the brain. Axon 
guidance molecules, the very molecular cues that regulate the 
formation of axon-target connections during development, may 
mediate these alterations. To test this hypothesis, we investigated 
mRNA expression changes of 39 axon guidance molecules, including 
17 Semaphorins, 12 Ephs, 8 Ephrins and 2 neuropilins in the 
mesolimbic dopamine system of cocaine-treated animals under 
different paradigms by mean of DNA-Microarray and quantitative 
real-time PCR. In all cases, strong changes in gene expression are 
observed, yielding to up or down-regulation of these axon guidance 
molecules. Our data suggest that cocaine treatment induces 
activation of a complex program of synaptic rearrangements, which 
may partly recapitulate the plastic changes occurring during 
development, and may underlie the important neuroplastic 
adaptations that occur in the reward- and memory-related brain 
centers following drug action. We conclude that in some brain 
regions, exposure to psychomotor-stimulant drugs produce 
expression changes in axon guidance molecules, which may 
contribute to cognitive deficits associated with drug abuse. 
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INTRODUCTION
Repeated exposure to drugs of abuse induces complex rewiring of 
neural circuitry that results in the behaviors associated with 
addiction (Chao and Nestler, 2004, Nestler 2000, Berke et al., 1998). 
Molecular adaptations following acute and chronic drug 
administration involve the mesolimbic dopamine (DA) system as the 
primary site affected in drug dependence and underlies strong 
plasticity in response to the drug (Schultz, 1998). Addictive drugs 
(cocaine and amphetamines), depressants (ethanol) and opiate 
narcotics (heroin and morphine) are very powerful reinforcers and 
produce their rewarding effects of euphoria or pleasure through an 
interaction with the mesolimbic DA system (Nestler, 1997). Within 
the tegmental area, interaction between neurotrophic factors or 
cytokines and drugs of abuse has been well established (Berhow et 
al., 1996; Nestler et al., 1996). CNTF mimics some of the long-term 
effects of cocaine and opiates in the tegmentum through its GP130 
receptor (Ip and Yancopoulos, 1996), which triggers the JAK-STAT 
pathway. There is also evidence for drug-regulated alterations of glial 
cells in the tegmentum (O’Callaghan and Miller, 1994). Major known 
neuronal adaptations include intracellular down-stream changes, 
such as decreases in GiD and GoD levels, changes in the cAMP 
pathway (Nestler et al., 1990), increases in tyrosine hydroxylase 
levels, and altered expression of transcription factors ('fosB) (Nestler 
et al., 1999, Moratalla et al, 1996, Moratalla et al., 1993), 
neurofilaments and phosphoproteins (D-internexin, NF-66) (Sklair-
Tavron 1996, Beitner-Johnson, 1992). Perturbation in the BDNF 
signaling cascade, yielding an increase of extracellular signal 
regulated kinase (ERK) and tyrosine hydroxylase induction has also 
been reported (Sklair-Tavron 1996; Berhow et al., 1995).
However alterations at synapses - a key process in drug-related 
plasticity - may be guided by the expression of axon guidance 
molecules (Grünwald, 2004, Gosh, 2002, Goldenschwegge et al., 2002, 
Atwal et al., 2004, Pasquale, 2000). Semaphorins might significantly 
contribute to the maintenance and stability of neuronal networks and 
play important roles in the regeneration, or failure thereof, of 
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neuronal connections (De Wit and Verhaagen, 2003). Eph receptors 
are involved in synaptic plasticity (Grünwald et al, 2001, Henderson 
et al, 2001) and several Eph molecules are upregulated after injury 
(Willson et al, 2002, Battaglia et al, 2003, Knöll et al, 2001). 
Nevertheless little is known about cell surface molecules involved in 
neuroadaptations after drug intake. Strong induction of a surface 
tetraspanin protein, CD81, has been described (Michna et al., 2001, 
Halladay et al., 2000, Brenz-Verca et al., 2001, Bahi et al., 2004). Also 
specific axon guidance cues, such as EphB1 and ephrin-B2, are 
expressed after challenges with psychomotor stimulants, (Zhou, 1998; 
Yue et al., 1999). These two complementary cues guide neurons 
during the development of the central nervous system for the 
establishment of topographic projections in the mesolimbic 
dopaminergic pathway (Yue et al., 1999), suggesting that the very 
cues that attract, repulse or hem axon growth cones on their way to 
their synaptic targets, are re-expressed in the adult brain after a drug 
challenge to the CNS. Alterations at synapses might therefore be 
guided by the very molecular cues that formed the projection-target 
connections during development. Based on this suggestion, we 
further tested this hypothesis on a large number of axon guidance 
molecules, namely the semaphorins and their cognate receptors, the 
neuropilins, and the Eph receptor tyrosine kinases and their cognate 
ligands, the Ephrins.
The semaphorins are among the best-studied axonal guidance 
molecules and appear to play key roles in these cellular events (Bagri 
et Tessier-Lavigne, 2002, Atwal et al., 2004, Püschel et al., 2002, Wit 
and Verhaagen, 2003). To date, more than 20 different semaphorins 
have been identified. They fall into eight groups on the basis of 
domain organization and species of origin, but all semaphorins 
contain a conserved, 500-amino-acid-length “Sema” domain at their 
amino-terminus (Püschel et al, 2002). This domain is also present in 
the plexin (Plex) family (Püschel et al, 2002). The other family of axon 
guidance molecules investigated in this study, the Eph receptors and 
ephrin ligands, have provided important insights into the molecular 
mechanisms underlying cellular interactions regulating axon 
guidance, cell migration, and morphogenesis (Flanagan and 
Vanderhagen, 1998). Interactions between ephrins and Ephs require 
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cell-cell contact, thereby raising the intriguing possibility that in some 
developmental contexts, signaling is bidirectional (Osterfield et al., 
2003).
We investigated the expression of these guidance cues in the 
mesolimbic dopamine system of cocaine-treated animals under 
various paradigms by means of DNA-Microarrays and quantitative 
real-time PCR. Drastic and complex changes in expression observed 
upon cocaine administration are discussed. 
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EXPERIMENTAL PROCEDURES
1. Animal Handling
Subjects used in this experiment were male Wistar rats weighing 225-
250 g (BRL, Fillingsdorf, Switzerland). All animal experiments were 
carried out in accordance with the guidelines and regulations for 
Animal Experimentation, BAG, Bern, Switzerland. The animals were 
housed in trios in clear plastic cages with wire grid lids. Access to 
food and water was unrestricted. The animals were kept in the 
animal facility maintained on a 12-h light: 12-h dark cycle (lights off 
at 19:00 h). 
Drug administration Protocols: Four different protocols were used in 
this study, depicted in Figure 1. These protocols represent different 
paradigms of drug administration, based on established 
methodologies and allow for good evaluation of drug-induced 
expression changes and pattern correlation among the various 
candidates. These included (a) an acute treatment, consisting of a 
single dose of cocaine (15 mg/kg, i.p.); (b) a binge treatment
consisting of four high doses (30 mg/kg i.p.) at two hours interval 
within a single day (c) a chronic treatment, consisting of a daily dose 
of cocaine (15 mg/kg i.p. over 15 days); and (d) a sensitization
protocol subdivided into four test groups. After sacrifice, four brain 
regions were dissected out (Hippocampus, Nucleus Accumbens, 
Striatum and Ventral Tegmental Area), the total RNA was extracted, 
amplified, labeled and hybridized onto microarrays. The remaining 
RNA was reverse transcribed for quantitative real-time PCR.  
Acute Paradigm: rats (n=6) were i.p. injected once with 15 mg/kg 
cocaine-HCl (Sigma Chemical Co., Buchs, Switzerland). Control 
animals received 0.9% saline i.p. injection. All the animals were 
sacrificed 24 h after the last injection by decapitation 
Binge Paradigm: rats (n=6) were i.p. injected with 30 mg/kg cocaine-
HCl (Sigma Chemical Co., Buchs, Switzerland) every 2 hours for 4 
injections. Control animals received 0.9% saline i.p. injection under 
the same schedule. All the animals were sacrificed 24 h after the last 
injection by decapitation 
Chronic Paradigm: rats (n=6) were daily i.p. injected with 15 mg/kg 
cocaine-HCl (Sigma Chemical Co., Buchs, Switzerland) for a period 
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of 15 days. Control animals received 0.9% saline i.p. injection under 
the same schedule. All the animals were sacrificed 24 hours after the 
last injection by decapitation  
Sensitization Paradigm (see Figure 1 for samples identification):
Four groups (n=6 per group) were used. Groups S1 and S2 represent 
control groups, treated with saline during an initial period, when 
groups S3 and S4 received cocaine over five days of sensitization. 
After a short withdrawal period (3 days, groups S1 and S3) or a long 
withdrawal period (14 days, groups S2 and S4), animals were 
challenged and sacrificed 24 h later 
S1 and S2 groups: rats were treated (“sensitized”) with daily i.p. 
injections of 0.9% saline during 5 days. On the 3rd day (group S1) or 
on the 14th day (group S2) after the last administration 
(“sensitization”), half of the groups were challenged with a single i.p. 
injection of 0.9% saline and the other half with a single i.p. injection 
of 15 mg/kg cocaine-HCl (Sigma Chemical Co., Buchs, Switzerland). 
Groups were sacrificed by decapitation 24 h later, on the 4th and the 
15th days for groups S1 and S2, respectively. 
For the S3 and S4 groups: rats were sensitized with daily i.p. 
injections of 15 mg/kg cocaine-HCl (Sigma Chemical Co., Buchs, 
Switzerland) during 5 days. On the 3rd day (group S3) or on the 14th
day (group S4) after the last sensitization, half of the groups were 
challenged with a single i.p. injection of 0.9% saline and the other half 
with a single i.p. injection of 15 mg/kg cocaine-HCl (Sigma Chemical 
Co.). Groups were sacrificed by decapitation 24 h later, on the 4th and 
the 15th days for groups S3 and S4, respectively. 
2. RNA Preparation and Microarray Hybridization
RNA Extraction: After sacrifice, brain regions were dissected out 
(Hippocampus, Nucleus Accumbens, Striatum and Ventral 
Tegmental Area), and the total RNA was extracted. In all cases brain 
regions were pooled before preparing RNA, since previous control 
experiments with unpooled samples had shown no statistical 
differences compared to pooled samples. 
Total RNA was isolated using RiboPure Kit (Ambion, UK) according 
to the manufacturer’s protocol. Briefly, 1 ml of RNAwiz was added to 
50 mg of tissue, homogenized with a Polytron homogenizer, vortexed 
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for 30 s and incubated at room temperature for 5 min. Residual 
protein was removed by the addition of 0.2 ml of chloroform, mixing 
for 30 s, incubation at room temperature for 5 min, vortexing for 
further 30 s, and centrifugation for 15 min at 12000 g and room 
temperature. The aqueous phase was precipitated with 0.5 ml of 
absolute ethanol, filtered over a column and washed by 
centrifugation. The total RNA was then eluted with 0.1 ml of DEPC-
treated water, incubated at 60 °C for 10 min and stored at –80 °C. 
RNA Amplification: This was performed according to Kacharmina et 
al. (1999). First Strand Synthesis was performed in 0.2 ml RNAse-free 
PCR tubes as follows: 2 Pg of total RNA was added to 9 Pl of 0.6M 
Trehalose in DEPC water and 1 Pg Eberwine oligo-dT/T7 primer 
(5'AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT 
AGG CGC T15-3'). These components were mixed well by pipetting 
and heated at 65°C for 10 minutes, then kept on ice. To the mixture 4 
Pl of 5X First Strand Buffer (Invitrogen, Basel, Switzerland) was 
added, followed by 2 Pl 0.1M DTT, 10 U RNAsin (Invitrogen, Basel, 
Switzerland), 1 Pl 10 mM dNTP mix (Promega, Wallisellen, 
Switzerland), 1 Pl linear acrylamide (0.1 mg/ml), 1 Pl 200 U/Pl
Superscript II RNaseH-Reverse Transcriptase (Invitrogen, Basel, 
Switzerland). The mixture was incubated in a thermocycler at: 37°C, 
5 min; 45° C, 5 min; then 25 cycles alternating between 60°C, 2 min 
and 55°C, 2 min. Tubes were kept on ice, while adding second strand 
components. Second Strand Synthesis was followed by adding 106 Pl
DEPC water, 15 Pl Second Strand Buffer [200 mM Tris pH 6.9, 900 
mM potassium chloride, 46 mM magnesium chloride, 1.5 mM 
Nicotine Adenine Dinucleotide (Calbiochem, Nottingham, UK), 100 
mM ammonum sulfate, 3 Pl 10 mM dNTP mix (Promega, Wallisellen, 
Switzerland), 10 U E. coli DNA Ligase (Bioconcept, Allschwill, 
Switzerland), 30 U E. coli DNA Polymerase I-holoenzyme 
(Bioconcept, Allschwill, Switzerland), 2 U RNase H (Invitrogen, 
Basel, Switzerland). The mixture was incubated at 16°C for 4 hours. 
The reaction was stopped with 7.5 Pl 1M NaOH/2mM EDTA with 
incubating at 65°C for 10 minutes. The double-stranded DNA was 
extracted once with Phenol:chloroform:isoamyl (25:24:1). 150 Pl of 
organics were added directly to PCR tubes, mixed and centrifuged 
8
ht
tp
://
do
c.
re
ro
.c
h
for 5 min at 15’000 g at room temperature. The aqueous phase was 
transferred to Rnase-free 1.5 l Eppendorf tube and DNA was 
precipitated with 70 Pl of 7.5 M ammonium acetate (in DEPC-water, 
0.2 micron filtered) and 1 ml absolute ethanol (-20°C). Tubes were 
vortexed and centrifuged immediately for 20 min at 15’000 g at room 
temperature. The pellet was washed once with 100 Pl absolute 
ethanol and resuspended in 10 Pl of DEPC-water. In vitro 
transcription was then performed with the Ambion T7 Megascript 
Kit (Ambion, UK), according to the manufacturer's protocol. 
Probe Preparation and Hybridisation: Each aRNA sample (one from 
control sample and one from treated sample) was reverse-transcribed 
in the presence of Cy3-dCTP (control samples) or Cy5-dCTP (treated 
samples) (Amersham Pharmacia Biotech, Dübendorf, Switzerland). 
Each reaction was performed in a 30 Pl volume containing 2 Pg of 
aRNA, 2 Pg of oligo(dT) 21-mer, 500 PM each of dATP, dGTP, and 
dTTP, 200 PM dCTP, 100 PM Cy3-dCTP or Cy5-dCTP, 30 units of 
RNase inhibitor, 10 M DTT, and 400 units of SuperScriptII reverse 
transcriptase (Invitrogen, Basel, Switzerland) in SuperScript buffer. 
After incubation at 42°C for 3 hours, the sample tubes containing Cy3 
and Cy5 labeling were pooled and treated with 2.65 Pl of 25 mM 
EDTA and 3.3 Pl of 1 M NaOH for 10 min at 65°C to degrade the 
RNA. After the addition of 3.3 Pl of 1 M HCl and 5 Pl of 1 M Tris-
HCl, pH 6.8, labeled single stranded DNA was precipitated with 0.1 
volume of 3 M sodium acetate and 2 volumes of absolute ethanol, 
and the pellet was washed with 80% ethanol, dried, and resuspended 
in 10 Pl of hybridization solution containing 3X SSC, 0.2% SDS, and 
0.02% yeast tRNA (Invitrogen, Basel, Switzerland). Probes were 
purified by Millipore (Volketswil, Switzerland) Ultrafree-MC filters. 
Hybridization Reaction and Microarray Analysis: Before
hybridization, the probe solution was boiled for 1 min and rapidly 
applied to the microarray under a cover slip. Slides were placed in 
hybridization chambers, and 20 Pl of 3X SSC was placed inside each 
chamber before sealing. Slides were incubated for 14 to 16 hours in a 
water bath at 64°C and washed sequentially in the following 
solutions: 2X SSC, 0.1% SDS twice for 5 min, 0.2X SSC twice for 1 min, 
and 0.1X SSC twice for 1 min. Slides were dried by centrifugation at 
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900 g for 2 min before scanning. 
Microarrays were scanned with a scanning laser microscope 
Affymetrix® 428™ Array Scanner; (Affymetrix, INC., Santa Clara 
US). Separate images were acquired for each fluorochrome at a 
resolution of 10 Pm per pixel. To normalize the two channels with 
respect to signal intensity, photomultiplier and laser power settings 
were adjusted such that the signal ratio of the control genes was as 
close to 1.0 as possible. The average fluorescence intensity for each 
fluorochrome and for each gene was determined by using Jaguar 2.0 
software (Affymetrix, INC., Santa Clara US). Background 
fluorescence was calculated as the median fluorescence signal of non-
target pixels around each gene spot. Induction or repression of a gene 
was defined as a minimum 1.5-fold change in its transcript level. 
Statistical Evaluation of Microarray data: Signal intensities of spots 
corresponding to a given candidate from three independent tissue 
samples, with mean standard deviation, were plotted as cocaine-
treated versus saline-treated probes. Quantification was presented as 
the ratio between experiments (Cy5-labeled samples) versus control 
(Cy3-labeled samples) changes in expression at mRNA level, after 
background substraction. The raw data were initially analyzed using 
Jaguar 2.0 (Affymetrix, INC., Santa Clara US), which calculates 
normalized expression levels and generates ratios of experimental 
(Cy5) versus control (Cy3) signals. Then data sets from comparison 
files were imported into Excel (Microsoft) for further analysis and p-
values calculations. A stringent cut-off was used for significance: 
genes were considered to be down regulated if the ratio of 
experimental vs. control was 2.0 (with p<0.01) and up-regulated if 
the ratio was 2 (with p<0.01). Significance was calculated using a t-
test (McClung and Nestler, 2003).
3. Microarray Design
Selected Gene Candidates (see Table 1): Microarray design was 
performed according to published methods (Shalon et al., 1996). 20 
control oligonucleotides were included consisting of 10 negative 
controls (oligonucleotides randomly generated with no expression 
within neither the mouse nor the rat genomes) and 10 positive 
controls: E-Actin (NM_031144), Transcription factor E2D (X17500),
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Lactate dehydrogenase A (NM_017025), Hsp70-1 (NM_031971),
Nuclear pore glycoprotein 62 (M62992), Ribophorin 20814 
(NM_031698), Ribosomal protein L5 (NM_031099) Ribosomal protein 
S9 (NM_031108, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (NM_017008) and Polyubiquitin (D16554). The means of 
values of the negative controls were considered as background and 
subtracted from all other data. Besides these positive and negative 
control oligonucleotides, the microarray included oligonucleotides 
corresponding to the 39 axon guidance gene candidates selected for 
this study, which are listed in Table 1. These were 17 members of the 
Semaphorin family, 2 members of their corresponding receptors 
(Neuropilin 1 and Neuropilin 2), 12 members of the Eph Receptor 
Tyrosine Kinase (7 members of the EphA family and 5 members of 
the EphB family) and 8 members of their corresponding Ephrin 
ligands (5 Ephrin-A and 3 Ephrin-B). Candidates, including gene ID 
and oligonucleotide sequences and BLAST reference are listed in 
Table1. Note: Oligonucleotides sequences of positive and negative 
controls are patented (QIAGEN™, Basel, Switzerland) and are not 
listed.
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Specific oligonucleotides were designed (see below) and sythetized 
with 5’-amino modification. Oligonucleotides were resuspended in 
1.5 M Betaine, 3X SSC to a final concentration of 40 PM and then 
arrayed (8 spots/oligo) onto QMT Aldehyde Slides (Quantifoil, 
Germany) by using a high precision OmniGrid Accent™ 
Microarrayer (GeneMachines, San Carlos, CA) equipped with four 
printing tips. Each candidate was spotted eight fold, providing 
hybridization replicates on the same slide. After printing, slides were 
allowed to dry, and unbound DNA was removed with 0.2% SDS and 
double-distilled water; covalently bound DNA was denatured for 2 
min in boiling water. Free aldehydes were reduced by soaking slides 
for 5 min in 68 mM Sodium Borohydride (dissolved in PBS 
containing 25% ethanol). Several washing steps were performed with 
0.2% SDS and double-distilled H2O; then slides were dried by 
centrifugation at 500g for 5 min and stored at room temperature for 
further hybridizations. 
Probe design and selection rules (QIAGEN™, Basel, Switzerland):
For each selected gene candidate, several 70mer probes were 
designed. Each probe was sequence optimized using BLAST (Basic 
Local Alignment Search Tool) for nucleotide sequence to minimize 
cross hybridization in the microarray experiments. The 70mers were 
also Tm-normalized to 78°C (±5°C) for a more stringent hybridization 
at higher temperatures. Where 70mers could not be designed within 
the specified Tm range, shorter- or longer-length oligos were 
substituted to maintain the stringent Tm conditions. In addition, each 
70mer was flanked by a 5' C6 amino linker. Designed oligo were 
chosen within 1000 bases from the 3' end of the gene sequence such 
as excluding contiguous single nucleotide base repeats, poly(N) tracts 
longer than 10 bases or hairpin structures with a stem-length longer 
than 9 bases. A normalized score was assigned to each oligo, based 
on the number of repeats, and with 70% identity to all other genes. 
Using BLAST, each oligo was aligned against all 59,018 
representative sequences in Rat UniGene Build Rn 90 and 62,758 
representative sequences in Rat UniGene Build Rn 108. Using the 
alignment with the candidate oligo versus the highest scoring non-
self gene, a BLAST percent identity score was computed, defined as 
the sequence that yielded the most matched bases in an alignment. 
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This BLAST percent identity was also referred to as cross-
hybridization identity of the oligo. This calculated cross-
hybridization identity was dependent on the size of the sequence 
database used to BLAST against oligo sequence, and the use of either 
gapped or no-gap alignment method. Furthermore, oligos could not 
have greater than 20 contiguous bases common to any other gene. 
Once oligo candidates were designed, satisfying all selection rules 
mentioned above, each oligo was ranked based on BLAST percent 
identity and one final oligo for each gene was selected with minimum 
percent identity or cross hybridization similarity. 
Real-Time PCR and mRNA Quantification
Total RNA was isolated from different brain regions using RiboPure 
Kit (Ambion, UK), according to the manufacturer’s protocol 
including a RNase-free DNase step, and stored at –80°C. RNA were 
quantified by spectrophotometry. Integrity of the RNA was verified 
by agarose gel electrophoresis and visualized with ethidium bromide 
staining. First strand cDNA was synthesized using 1Pg of total RNA 
and Oligo(dT) primers with the M-MLV reverse transcription kit 
(Invitrogen, Basel, Switzerland) in a total volume of 15 Pl . 
Real-time PCR was performed to confirm Microarray results. Primer 
sets were designed to amplify 100- to 300-bp products, using 
PRIMER3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
To quantify expression of cDNAs the real-time PCR iCycler (BioRad, 
Reinach, Switzerland) was used. For PCR, 5Pl cDNA preparation, 
0.5PM of forward and reverse primers and 10Pl of IQ SYBR Green 
Supermix (Biorad, Reinach, Switzerland) in a total volume of 20Pl
were applied. The following PCR program was performed: 3 min at 
95°C (initial denaturation); 20°C/sec temperature transition rate up 
to 95°C for 30 sec, 45 sec 62°C, repeated for 40 times (amplification). 
The PCR reaction was evaluated by melting curve analysis following 
the manufacturer’s instructions and checking the PCR products on 
2% agarose gel. 
The PCR cycle number at which each assay target reached the 
threshold detection line was determined (Ct value). cDNA samples 
were assayed on at least 3 dilutions to check for assay reliability 
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using duplicate assay on each dilution. The ¨Ct for each candidate 
was calculated as ¨Ct = [Ct (candidate) – Ct (GAPDH or E-Actin)].
The relative abundance of each target in each protocol can be 
calculated as the ratio between treated and untreated samples 
(Mühlbauer et al., 2004). 
GAPDH and E-Actin were used as endogenous controls for 
normalization. No difference was observed between these two genes 
for all quantifications (data not shown). 
Statistical Analysis: Statistical significance was evaluated by the 
two-tailed Student’s t-test. P<0.05 was considered statistically 
significant.
14
ht
tp
://
do
c.
re
ro
.c
h
RESULTS
The aim of this study was to investigate plasticity changes induced 
by drug administration. Preliminary investigations in our lab, based 
on differential display with semaphorin-targeted primers, identified 
several axon guidance molecules as suitable candidates involved in 
drug-induced neuroadaptations (Widmer, 2000). Based on these 
findings a microarray was designed, containing 39 guidance cues 
together with 10 positive and 10 negative control genes (Table 1), 
with a view of evaluating expression changes in four different brain 
regions under various paradigms of drug treatment (Figure 1). The 
results are summarized in Figures 2 and 3. As shown in Figure 2 
(upper panel), positive controls displayed no change in expression in 
the brain areas under investigation, whatever the drug 
administration protocol: in all cases, the expression ratios of cocaine-
treated versus saline-treated animals were almost equal to 1.0, with 
<8.5% variation. Data were statistically highly coherent in all brain 
regions and under any tested condition. Each data represents the 
average of eight different hybridization slots from three independent 
tissue samples. Slightly higher variations were observed in the CPu 
of acute-treated animals or in chronically treated animals; but such 
variations were always within very small limits and were supported 
with very significant statistical correlation for all these control 
candidates. From these data, a 1.5-fold change in gene expression can 
be considered as significant. However only two-fold changes or 
higher will be discussed here. 
Drug-induced expression changes of Semaphorin: Expression changes 
of semaphorins are depicted in Figure 2.
In the hippocampus, six Semaphorins displayed high (2.5 to 8-fold) 
induction, namely Sema3A, Sema3B, Sema3E, Sema6A, Sema4C and 
Sema5A. Changes were highest in groups S4 (animals sensitized with 
cocaine and challenged after long term-withdrawal) or after chronic 
treatment. Between 8 and 4-fold up-regulation were observed with 
these candidates, depending upon regimen, with 
Sema5A>Sema4C=Sema3E>Sema3B. By contrast Sema3C, Sema6C 
and Sema4G were strongly down regulated (8- to 4-fold, with 
Sema4G>Sema6C>Sema3C), mostly after acute treatment. A number 
of other Semaphorins also displayed expression changes upon 
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cocaine, but to a lesser degree. Correspondingly, neuropilin-1 and –2, 
which are receptors for soluble semaphorins (Sema3 family 
members), displayed 2.5 - 4.5 fold up-regulation in this brain region, 
and the effect was strongest in S4 and chronic groups. 
In the Nucleus Accumbens strong down-regulation was observed in 
many cases, particularly in acute groups. Sema3A, Sema3E, Sema3F, 
Sema4G, Sema5B and Sema7A displayed >3.5-fold down-regulation 
after acute treatment and significant down-regulation in all other 
groups, chronic groups being least affected. Strong up-regulation was 
observed with most other candidates, particularly after chronic 
treatment, where >8-fold changes were observed 
(Sema3B>Sema4C=Sema4B>Sema6B>Sema3C=Sema4A>Sema4F).
Two candidates, Sema5A and Sema6A were little affected by cocaine 
in this region in all protocols. Receptors for soluble Semaphorins, 
Neuropilin-1 and Neuropilin-2, were also induced in this brain 
region under all conditions, mainly in chronic groups (ca 5-fold 
induction). 
In the Caudate Putamen, changes were less important. However, 
some candidates displayed high expression changes: Sema4C was 
highly up regulated, about 10-fold in S4 groups, 7-fold in chronic 
groups and 5.5-fold in binge groups. Other candidates displaying 
strong changes included Sema4A, Sema4B and Sema3E (5-6-fold over 
expressed in S4 groups, >4-fold in chronic and binge groups) and 
Sema3F (>4-fold up-regulated in chronic and S4 groups). In contrast 
Sema4D was about 8-fold down-regulated in acute groups and 
Sema3A, Sema5B, Sema7A and particularly Sema6C were down 
regulated (4- to 6-fold, depending upon regimen). Neuropilins were 
up regulated 3- to 5-fold in all groups. 
In the Ventral Tegmental Area, greatest changes were observed with 
most members of the Sema3, Sema4 and Sema7 and mainly in either 
acute or in S4 groups. Strong up-regulation was observed generally, 
but Sema3E and Sema4G were down regulated. In S4 groups, up to 
>6-fold up-regulation was found for Sema3A, Sema3C, Sema4B, and 
Sema4C, and about 10-fold up-regulation for Sema4D, sema4F and 
Sema5A. Acute treatment has little effects in expression changes for 
these candidates, but binge and chronic treatments induce 3-5 fold 
up-regulation. Down-regulation in this region was highest in acute 
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treatments and involved a few candidates: Sema3E (6-fold in acute 
and S4 groups), Sema4G (7-fold in acute groups), Sema5B and 
Sema7A (4-fold in acute groups). Sema4A was poorly affected, except 
in acute treatment (4-fold down-regulation). 
In all regions, one candidate (Sema6C) displayed strong down-
regulation under all protocols whereas Sema4B, Sema4C and 
neuropilins were up regulated in each region and under all 
conditions. Furthermore most candidates (except Sema3A, and 
Sema3F) displayed similar patterns of expression changes both in the 
Nucleus Accumbens and in the Ventral Tegmental Area the major 
dopaminergic regions included in this study.
Clearly, the observed expression changes are very consistent, the 
changes of a single candidate in a given region being very similar, 
independent of the treatment, with only relative intensities being 
affected. All the changes observed from microarray data could be 
confirmed by real-time PCR (Figure 4) and the same pattern of 
changes was observed in all cases. Figure 4 displays a comparison of 
the data from qRT-PCR and microarray for major conditions, i.e. 
where greatest changes in expression were observed (about 15% of 
the conditions tested by microarray): in all cases both sets of data 
matched perfectly. Table 3 displays the statistical analysis of the 
candidates modified by cocaine on microarray and whose expression 
change has been confirmed by qRT-PCR. Changes observed in the 
Nucleus Accumbens on chronically treated animals are very 
significant for Sema3B, Sema4B, Sema4C and to a lesser extend for 
Sema3E and NP-1. In the Ventral Tegmental Area most significant 
changes are observed on chronocally treated animals for Sema3C, 
and Sema5A, whereas changes observed for Sema3C, Sema3E, 
Sema3f, Sema4G, Sema5A, Sema5B and NP-1 are highly significant in 
S4 groups. NP-1 and Sema3E display very significant changes in all 
regions under most conditions. 
Drug-induced expression changes of Eph’s and Ephrins:
Neuroadaptations after drug treatment also strongly affected 
expression of Eph’s receptor tyrosine kinase and their ligands, as 
shown in figures 3. Changes are very significant, although less 
intense for these families of axon guidance molecules. 
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In the Hippocampus, all Eph and Ephrins were slightly up regulated. 
Only in S4 groups and sometimes in acute groups were >2-fold up-
regulations observed for EphA’s. For EphB’s, changes are >2-fold in 
acute groups as well as in S4 groups. Greatest changes were observed 
with Eph-B1, EphB4 and EphB2. The corresponding ligands, Ephrins, 
were also up regulated in all cases, but Ephrin-A’s displayed little 
changes (2-fold) except in S4 groups (2-4 fold up-regulation). 
Ephrin-B’s, by contrast, were more affected by regimen: S4 and S3 
groups displayed ca. 6- and 4-fold up-regulation, respectively while 
in acute and chronic groups gene expression increased 3-4 fold. 
In the Nucleus Accumbens, Eph-A are little affected and >2-fold 
changes were observed only after chronic treatments or sometimes in 
acute groups (see Eph-A5 and Eph-A8). Their ligands Ephrin-A’s 
displayed comparable adaptation, greatest changes being observed 
after chronic treatments (about 4-fold up-regulation in all cases). Eph-
B’s displayed more important up-regulation: again greatest induction 
pattern were found after chronic treatments (4-6 fold up-regulation), 
but acute and binge treatments also strongly affected Eph-B2, Eph-B3 
and Eph-B4 (3-5 fold up-regulation). Furthermore, S3 and S4 groups 
were also strongly affected (4-6 fold up-regulation). Greatest changes 
were observed with Eph-B4 in all protocols (4-8 fold up-regulation). 
The corresponding Ephrin-B’s ligands were also induced after drug 
administration under all protocols, mostly after chronic treatment (4-
6 fold up-regulation). 
In the Caudate Putamen expression changes of Eph-A and Ephrin-A 
were more complex. Three Eph-A1, EphA3 and Eph-A5 were down 
regulated together with their ligands Ephrin-A1 and Ephrin-A3; this 
effect was most important (6-7 fold down-regulation) after acute 
treatments for Eph-A1, Eph-A3 and the two Ephrins. By contrast, the 
other Eph-A’s like the other Ephrin-A’s were rather over expressed 
(2-fold in most cases, but slightly >2-fold in S4 groups). For Eph-B’s 
and Ephrin-B’s up-regulation was observed in all cases; this effect 
was most important for Eph-B4 (4-6 fold up-regulation) and to a 
lesser extent for Ephrin-B2 and Ephrin-B3. 
In the Ventral Tegmental Area, no great changes were observed. 
Only S4 groups displayed >2-fold changes in Eph-A expression while 
Ephrin-A’s were not much affected either. Ephrin-A1 and Ephrin-A3 
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were 3-fold down regulated after acute treatment. For Eph-B3, Eph-
B4 and Eph-B6 also expression was not much changed in this region. 
By contrast, the other Eph-B’s and their corresponding Ephrins 
displayed stronger induction: with Eph-B1 and Eph-B2, 3-fold up-
regulation after chronic and binge treatments, and 6-fold up-
regulation in S4 groups were observed, which matched with 2-4 fold 
up-regulation and 4-6 fold up-regulation under the same regimen, 
respectively, of Ephrin-B1 and Ephrin-B2. 
Expression changes observed on microarrays for Eph’s and Ephrins 
have been confirmed by means of qRT-PCR. Figure 4 displays the 
comparison of microarray data and qRT-PCR. For simplicity only the 
most characteristic expression changes of Eph’s and Ephrins in the 
four brain regions are displayed (representing 14% of the conditions 
tested by microarray). As shown in Figure 4, qRT-PCR fully 
corroborated the changes observed in microarray data, in all cases, 
without exception, and in most cases the values of the both sets of 
data matched perfectly. Statistical analysis of changes observed by 
these candidates (Table 3) shows robust changes in the Caudate 
Putamen under acute treatment for EphA1, EphA2 and their partner 
ligands EphrinA1 and EphrinA3. Under chronic treatment, most 
robust changes were observed with EphB’s in the Nucleus 
Accumbens and in the Hippocampus.
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DISCUSSION
A gene profiling of a number of axon guidance molecule transcripts 
in several protocols of drug administration has been undertaken in 
this study, with a view to determine their involvement in drug-
induced neuroadaptations. These plasticity-related secreted or cell 
surface molecules are developmentally regulated cues that play a 
major function during development and direct the projection of the 
extending axon growth cone to its synaptic target, enabling proper 
formation of neuronal synapses. A role in the adult brain, however, 
has been poorly described in a few cases only (De Wit and 
Verhaagen, 2003). For example, specific re-expression of EphB1 and 
ephrinB2 was observed in the adult, following a drug challenge (Yue 
et al., 1999), a finding consistent with the notion that long-term, 
molecular adaptations of neurons following exposure to drugs of 
abuse underlie a complex rewiring of neural circuitry that results in 
the behaviors associated with addiction (Bardo, 1998, Wang and 
McGinty, 1997, Nestler and Aghajanian, 1997, Robinson and 
Berridge, 1993). Based on this observation, a gene profiling of two 
classes of axon guidance molecules, the semaphorins and 
Ephs/ephrins, was investigated in the present study in different 
protocols of drug administration.  
Drug-induced Plasticity involves Expression Changes of a Combination of 
Semaphorins and related Receptors: Semaphorins are a large family of 
secreted, GPI-linked or transmembrane proteins that may bind to 
neuropilins (secreted Sema-3) and/or plexins and function as 
chemorepellents or inhibitors of growth cones (Yu and Bargmann, 
2001, Skoliora et al, 1998). The function of Semaphorins in the adult 
brain is poorly described, but a role in regeneration of injured nerve 
fibres is well documented (De Wit and Verhaagen, 2003). During 
development, different semaphorins are generally co-expressed and 
interact in synergistic ways, innervation specificity being achieved 
through the combined action of multiple guidance cues (Steup et al., 
1999, Skaliora et al., 1998). For example, during development most 
striatal and cortical interneurons arise from the basal telencephalon, 
whose migration is controlled by chemorepulsive signal composed 
mainly of semaphorin 3A and semaphorin 3F (Marin et al., 2001) and 
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migrating interneurons expressing neuropilins are directed to the 
cortex, while those lacking them go to the striatum. Recent studies 
have revealed extensive regulation of these cues and their receptors 
as well as combinatorial mechanisms that integrate information from 
different families of guidance cues (Yu and Bargmann, 2001). The 
combinatorial and simultaneous input of multiple guidance cues, i.e. 
the relative balance of attractive (growth-promoting) and repulsive 
(growth-inhibiting) forces, provides synapse specificity by allowing 
axons to select various subsets of nerve cells as their targets. 
Our study suggests similar synergistic mechanisms in the adult brain 
after drug administration: drug-induced plasticity involves the 
regulation of several semaphorins and their related neuropilin 
receptors. All members of the five classes of semaphorins included in 
this study display strong expression changes (>6-fold, except 
Sema6A and Sema6B) in at least one condition or region, highest 
changes affecting Sema3A, Sema3B, Sema4B, Sema4C, Sema4F and 
Sema5A (for nomenclature, see Semaphorin Nomenclature 
Committee, 1999).
Drug-induced neuroadaptations is known to primarly affect the 
mesolimbic dopaminergic pathway (Robinson and Berridge, 1993, 
Nestler, 2000). In this pathway, cocaine induced largest expression 
changes of many semaphorins, mainly Sema3A, Sema3B, Sema3F, 
Sema4B, and Sema4C in the Nucleus Accumbens, and Sema3C, 
Sema3E, Sema4D, Sema4F, Sema4G, Sema5A, Sema5B and Sema7A 
in the Ventral Tegmental Area.
Sema3 are secreted proteins and act generally as repellents of 
different classes of axons and their regulation in the adult brain has 
been described in some disorders. Aberrant expression or signalling 
of secreted Semaphorins might be of significance in altered structural 
plasticity in neurodegenerative disorders such as Alzheimer (Good et 
al, 2002). Sema3A is the most potent repellent and repels axons that 
are responsive to NGF (Messersmith et al, 2001), but this depends 
upon the age of the animal (Puschel et al., 1996). Sema3A and its 
ligand Neuropilin-1 are temporarily down-regulated in the 
hippocampus in epileptic rat brain, correlating with robust mossy 
fiber sprouting into the molecular layer, a layer normally devoted of 
mossy fibers. Kainate-induced status epilepticus also induces a 
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persistent down-regulation of Sema3C and Sema3F (Barnes et al., 
2003). We found Sema3F to be strongly down regulated in the 
Nucleus Accumbens after acute treatment and up regulated in other 
regions, particularly in the Ventral Tegmental Area and the 
Hippocampus in chronic or S4 groups. This candidate may suppress 
NGF-induced activation of PI3-kinase-Akt and dampen neutrophin 
signalling, a novel mechanism of semaphorin-mediated growth cone 
collapse, providing an intracellular mechanism for cross talk between 
positive and negative axon growth cues (Atwal et al., 2003).
Sema4C is a transmembrane semaphorin that binds to proteins 
involved in neurite outgrowth; its strong up-regulation (8-fold) in 
chronic groups in the Nucleus Accumbens, Hippocampus and 
striatum may regulate drug-induced plasticity in these areas.  
Sema4F, which is strongly up regulated after cocaine in the Ventral 
Tegmental Area, interacts with PSD-95, a scaffold protein which 
concentrates ion channels, adhesion molecules and neurotransmitter 
receptors at the post-synaptic membrane (Sheng, 2001). Sema4D 
associates with cytosolic kinases and binds to proteins involved in 
neurite outgrowth and cytoskeletal reorganization. These interactions 
regulate actin dynamics and neurotransmitter receptor clustering, 
transport and docking of synaptic vesicles and thus modulate spine 
plasticity (De Wit and Verhaagen, 2003).  
Sema5A is a transmembrane protein with seven thrombospondin 
repeats. It acts as a permissive cue for growing axons (Adams et al., 
1996, Neugebauer et al., 1991, Simmons et al, 1998), although a recent 
report shows that its expression by oligodendrocyte lineage cells 
contributes to the glial cues that inhibit CNS regeneration. (Goldberg 
et al., 2004). Sema5A may be responsible for some of the features of 
the Cri-du-chat syndrome of mental retardation since the gene covers 
at least 10 percent of the deleted region (Simmons et al., 1998, Inagaki 
et al., 1995). It is strongly up-regulated (8-fold) in chronic groups in 
the Hippocampus and to a lesser extend in the Ventral Tegmental 
Area, but it is down regulated in the striatum.
Sema6C, which is strongly down regulated in all brain regions and in 
all conditions, is highly expressed in the lateral ventricle, the 
striatum, the midbrain, the pons/midbrain junction, and the choroid 
plexus (Qu et al., 2002). Finally, Sema7A, a 
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glycosylphosphatidylinositol-linked semaphorin strongly down-
regulated in the Ventral Tegmental Area after drug treatment, 
displays highest expression in the nervous system and in the adult 
brain (Sato and Takahashi, 1998, Xu et al., 1998, Lange et al., 1998) 
and promotes axon growth through integrin receptors (Pasterkamp 
et al, 2003). 
From our study, one is surprised that such a large variety of 
semaphorins and related receptors display expression changes after 
drug treatment. On the other hand, splice variants of semaphorin 
RNA transcripts also are important for regulating plasticity in 
neurons (Daoud et al., 1999) and nonfunctional isoforms of 
semaphorin genes, produced through alternative splicing, may be 
used as regulators of that gene’s activity. Furthermore, neuronal 
activity alters splice patterns (Daoud et al., 1999) and cocaine 
administration stimulates this activity. Together this may further 
complicate the pattern and to some extent explain the large diversity 
of expression pattern of the axon guidance cues identified in this 
study.
Eph receptors and related Ephrin ligands display significant changes after 
drug treatment, but of lower intensity than the semaphorins: The Eph 
family receptor tyrosine kinases include at least 14 receptors and 8 
Ephrin ligands (Zhou, 1998) that guide migrating cells and neuronal 
growth cones to specific destinations by repulsive mechanisms 
during development of the nervous system (Cheng et al., 1995, 
Drescher et al., 1995, Feldheim et al., 1998, Gao et al., 1996, Gao et al., 
1998). The ligands and receptors are often expressed in opposing 
gradients, and the ligand–receptor interaction restricts receptor-rich 
axons to ligand poor areas. Because Eph receptors and ephrins have 
complementary expression, bidirectional activation of Eph receptors 
and ephrin-B occur at interfaces of their expression domains 
(Mellitzer et al., 1999). 
In our study we found complementary up-regulation of Eph and 
their partner ligands, the Ephrin in the Ventral Tegmental Area and 
in the Nucleus Accumbens after all drug treatments. The up-
regulation is very significant, although of lower magnitude than 
changes observed with semaphorins. Similar complementary 
expression of EphB1 and Ephrin-B2 has been described in the 
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nigrostriatal and mesolimbic pathways in the adult after cocaine 
treatment (Yue et al., 1999). Dopamine activity regulates 
developmental expression of EphB1 and Ephrin-B2, whereas cocaine 
administration produced a significant elevation in Ephrin-B2 
expression in the Nucleus Accumbens. 
Highest changes after drug treatment are found in the Nucleus 
Accumbens with EphB4, EphB3 and EphB1 in chronically treated 
animals. By contrast down regulated in the striatum (CPu) is 
observed with specific EphA and EphrinA. The nature of the specific 
neural pathways implicated remains to be clarified in more details.
EphA4 and Ephrin-A3 are both up-regulated in the hippocampus. 
Murai has shown that expression of and signalling through Ephrin-
A3/EphA4 are critical for spine morphology of CA1 pyramidal 
neurons in the hippocampus (Murai et al, 2003) and for maintaining a 
stable and dynamic organization of spines during synaptic  
remodelling in the adult brain, whereas EphB receptor activation 
induces modest changes in dendritic spines in CA1. Changes in 
hippocampal spine density and dimensions occur in several mental 
disorders, including depression, schizophrenia and addiction.  
Another study has shown that EphB1, EphB2, and EphB3 are 
involved all three, although to varying degrees, in dendritic spine 
morphogenesis and synapse formation in the hippocampus 
(Henkemeyer et al, 2003). All these candidates are up regulated in 
that region in all protocols of drug administration 
Drug-induced Expression Changes of axon guidance cues may be related to 
plasticity and learning in addiction: In drug addiction the value of the 
drug and drug-related stimuli is enhanced, at the expense of other 
reinforcers, as a consequence of conditioned learning. The memory of 
the expected reward results in over activation of the reward and 
motivation circuits while decreasing the activity in the cognitive 
control circuit, which contributes to an inability to inhibit the drive to 
consume the drug (Volkow et al., 2003). Thus conditioned-learned 
associations and cognitive control is a key process in drug addiction. 
On the other hand several studies have implied axon guidance cues 
in synaptic plasticity and learning (Gerlai et al., 2001). EphB2 
regulates NMDA-dependent synaptic function and is up regulated in 
hippocampal pyramidal neurons by stimuli known to induce changes 
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in synaptic structure (Henderson et al., 2001). Mice lacking EphB2 
have normal hippocampal synapse morphology, but display defects 
in synaptic plasticity (Grunwald et al, 2001), long-term potentiation 
(LTP) is impaired, and two forms of synaptic depression are 
completely extinguished (Gosh, 2002, Grunwald et al., 2001, 
Henderson et al., 2001). Conditional ablation of Ephrin-B2 and 
Ephrin-B3, or of EphA4, a high-affinity receptor for these ligands, 
causes comparable defects in LTP (Grunwald et al., 2004). By 
contrast, in our study we found up to four-fold induction of EphB2 in 
the hippocampus, which theoretically should result in improved LTP 
and thus may be linked to  improved cue-mediated conditioned 
learning as observed in addiction.
On the other hand regulation of neurogenesis is a form of plasticity in 
the adult rat hippocampus. It has been proposed that drug regulation 
of neurogenesis in the adult rat hippocampus may be one mechanism 
by which drug exposure influences hippocampal function (Eisch et 
al., 2000). Thus drug-induced expression of axon guidance cues, 
particularly the Ephs and Ephrins, may be part of this process, which 
may recapitulate expression patterns of cues induced in earlier stages 
during development. In the adult brain, for example, EphB signalling 
regulates neural stem cell migration and possibly proliferation and 
EphB2 and Ephrin-B2, which both are induced by drug treatment in 
our study, has been shown to substantially increase the number of 
neural stem cells (Hinamen et al., 2003).
Effect of the drug administration paradigm on gene regulation: In this 
study, different drug administration paradigms have been used to 
assess expression changes of plasticity-related cell surface guidance 
cues. In most cases, chronic treatment or S4 sensitization groups 
display highest intensities in expression changes compared to other 
treatments within a given area. Expression changes of a given 
candidate within a specific brain region do not qualitatively differ 
from one paradigm to another, whereas only the intensity of the 
observed change is affected and strongly depends upon the type of 
treatment, with some exceptions. Therefore, under most 
circumstances, changes observed with a candidate in one paradigm 
will be observed also upon other treatments, but at a different 
intensity: wherever a candidate is up- or down-regulated, the 
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regimen does not influence this effect, only its magnitude. Some 
exceptions are observed, however, but mainly where expression 
changes of the candidate are of small intensity (<2-fold change).
In several conditions, acute treatment induces strongest changes, 
while the other treatments have small effects, i.e. for Sema3A and 
Sema3F in the Nucleus Accumbens, Sema4A and Sema4G in the 
Ventral Tegmental Area, Sema7A (several regions), and Ephrin-A3 in 
the Caudate Putamen, etc. It is therefore somewhat surprising that a 
single dose of drug may induces strong changes, where repeated 
doses produce lower expression change of the same candidate. This 
may imply a complex program of compensatory regulation and 
temporal adaptations of these guidance cues. 
In conclusion, we describe differential regulation of a large array of 
guidance cues in several brain regions in response to cocaine. The 
involvement of multiple Semaphorins, Neuropilins, Ephs and 
Ephrins in cocaine action suggests the activation of a complex 
program of synaptic rearrangements induced by the drug, which 
may recapitulate the plastic changes occurring during development 
in terms of mechanisms and of the molecular players involved. Local 
expression changes of these cues may mediate cytoskeleton 
rearrangement via  signalling and induce synaptic plasticity, through 
mechanisms similar to synaptic  targeting during development (Yue 
et al, 2002). These cues display a high range of functional 
characteristics, illustrating the complexity and the variability of 
neuroadaptations induced in the brain by psychostimulant 
treatment. Furthermore alternative splicing forms of these molecules 
have been described in many cases, which affect their binding and  
signalling properties, further complicating the pattern. The changes 
observed in this study are consistent with a role in addiction and 
may contribute to drug-related reinforcing of the mesolimbic circuits. 
Clearly, important neuroplastic changes occur in the reward- and 
memory-related brain centers following drug action. Together, these 
finding help clarifying the molecular and cellular events involved in 
early stages of drug addiction. The fact that the candidates 
investigated in this study regulate both axon guidance, during 
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development, and postnatal synaptic function emphasizes the varied 
roles of these cues in regulating cell-cell interaction within the CNS. 
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Figure Legends
Figure 1. Protocols of Drug administration.
A) Acute Treatment. Animals (n=6) are injected a single dose of 
cocaine (15 mg/kg) and sacrificed 24 h after injection.
B) Binge Treatment. Animals (n=6) receive four injections of high 
dose cocaine (30 mg/kg) and are sacrificed 24 h after the last 
injection.
C) Chronic Treatment. Animals (n=6) receive a single dose of cocaine 
(15 mg/kg) every day over 15 days and are sacrificed 24 h after the 
last injection. In each treatment (acute, binge or chronic), control 
animals were injected saline. In each cases aRNA samples of brain 
regions from controls (reverse transcribed as Cy3-dCTP) and from 
treated animals (reverse-transcribed as Cy5-dCTP) were prepared, 
hybridized on microarrays and the ratios measured. 
D) Sensitization Treatment. Four groups of animals (n=6) are used. 
Each group receives initially five daily injections of either saline 
(groups S1 and S2) or cocaine (15 mg/kg, groups S3 and S4).
Short withdrawal groups: three days after the last injection, groups S1 
and S3 are challenged with a single dose of either saline (group S1) or 
cocaine (15 mg/kg, group S3) and sacrificed 24 h after the injection. 
Long withdrawal groups: fourteen days after the last injection, groups 
S2 and S4 are challenged a single dose of either saline (group S2) or 
cocaine (15 mg/kg, group S4) and sacrificed 24 h after the last 
injection.
Groups S1 and S2 are animals sensitized with saline and challenged 
after a short withdrawal period (3 days, group S1) or a long 
withdrawal period (14 days, group S2). Groups S3 and S4 are animals 
sensitized with cocaine and challenged after a short withdrawal 
period (3 days, group S3) or a long withdrawal period (14 days, 
group S4). aRNA samples of brain regions from controls (challenged 
with saline, reverse transcribed as Cy3-dCTP) and from treated 
samples (challenged with cocaine, reverse-transcribed as Cy5-dCTP) 
were prepared, hybridized on microarrays and the ratios measured. 
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Figure 2. Expression Patterns of Controls and Semaphorins.
Upper panel: Expression changes of the 10 positive control genes are 
represented as ratios of cocaine-treated versus saline-treated samples 
from tissues of the four regions under investigation, each at the seven 
different conditions of drug administration.
Lower panel: Expression changes of the Semaphorins, in the same 
regions and conditions as in the upper panel. 
Microarrays were scanned with a scanning laser microscope 
(Methods section). Each bar represents the means of ratios from 8 
hybridization spots per gene from three independent tissue samples 
for a single treatment paradigm, with standard deviation (see 
Material and Methods section for details). Standard deviation was 
<8.5% in all cases. Color codes: as indicated in the figure, 
corresponding each to different drug administration protocols.
For all control genes no significant change of expression is observed 
under any condition and the ratio between samples from cocaine-
treated and saline-treated tissues is almost 1.0. 
E2a: Transcription factor E2LDH-A   : Lactate dehydrogenase 
A, HSP70: Heat Shock Protein 70, GP62: Nuclear Pore Glycoprotein 
62,
H: Hippocampus, A: Nucleus Accumbens, C: Caudate Putamen, V:
Ventral Tegmentum Area.
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Figure 3. Expression Patterns of Neuropilins, Eph’s and Ephrins. 
Upper panel: Expression changes of the Neuropilins, NP-1 and NP-2. 
Middle panel: Expression changes of the Eph-A and their 
corresponding ligands, the Ephrin-A. 
Lower panel: Expression changes of the Eph-B and their 
corresponding ligands, the Ephrin-B. 
Same representations as in figure 2, in the same regions and 
conditions of drug administration, with standard deviations. The 
same color codes in figure 2 (as indicated) are used for representing 
the different treatment conditions. Each bar represents the means of 
ratios (sample from cocaine-treated tissue versus sample from saline 
treated tissue) from 8 hybridization spots per gene from three 
independent tissue samples for a single treatment paradigm, with 
standard deviation. Standard deviation was <8.5% in all cases.
NP1: Neuropilin1, NP2: Neuropilin2. 
H: Hippocampus, A: Nucleus Accumbens, C: Caudate Putamen, V:
Ventral Tegmentum Area. 
Figure 4. mRNA Quantification of Candidate Transcripts: 
Comparison of Quantitative Real-Time PCR and Microarray.
QRT-PCR: quantification of gene transcripts by means of quantitative 
real-time PCR. Microarray:  quantification of gene transcripts on 
microarray (see figures 2 and 3 and Material and Methods). 
Colour codes correspond to the different protocols (as indicated 
within the figure), and are as in Figure 2 & 3. H: Hippocampus; A:
Nucleus Accumbens; C: Caudate Putamen; V: Ventral Tegmental 
Area. Standard deviation for RT-PCR was <4%, and for microarrays 
<8.5%, in all cases. 
For qRT-PCR, the relative abundance of candidate transcripts in total 
RNA from different tissue samples and from different  protocols was 
determined by real-time RT-PCR and expressed relative to GAPDH 
for replicate determinations (as described in the “Materials and 
Methods”). After normalization, the ratios between samples from 
cocaine-treated and saline-treated tissues were calculated.
40
ht
tp
://
do
c.
re
ro
.c
h
Fig. 1 
1 15 16
CHRONIC
Days
1 2
ACUTE BINGE
Days 1 2 Days
Sacrifice - Dissection
Saline Injection Cocaine Injection Saline Challenge Cocaine Challenge
Group S1
Saline Sensitization
Saline or Cocaine Challenge
3 days Withdrawal
Group S2
Saline Sensitization
Saline or Cocaine Challenge
14 days Withdrawal
Group S3
Cocaine Sensitization
Saline or Cocaine Challenge
3 days Withdrawal
Group S4
Cocaine Sensitization
Saline or Cocaine Challenge
14 days Withdrawal
SENSITIZATION
8  9
Days 1-5
Development of
Sensitization
SALINE
Days
8  9
Days 1-5
Development of
Sensitization
COCAINE
Days
Days20 21
Days 1-5
Development of
Sensitization
SALINE
DAYS 6-20
Withrawal
20 21
Days 1-5
Development of
Sensitization
COCAINE
Days
DAYS 6-20
Withrawal
Group Sensitization Withrawa l Challenge Sub-Group
Saline (dCTP-Cy3) Contro lS1 Sal ine 3 Da ys
Cocaine (dCTP-Cy5) Treated
Saline (dCTP-Cy3) Contro lS3 Coc a in e 3 Da ys
Cocaine (dCTP-Cy5) Treated
Sa line  (dCTP -Cy3) Contro lS2 Sal ine 14 Da ys
Cocaine  (dCTP-Cy5) Treated
Sa line  (dCTP -Cy3) Contro lS4 Coca ine 14 Da ys
Cocaine  (dCTP-Cy5) Treated
ht
tp
://
do
c.
re
ro
.c
h
Fig. 2 
CONTROLS
H A C V H A C V
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
H
S
P
7
0
N
u
cl
e
a
r
G
P
6
2
R
IB
O
P
H
O
R
IN
2
0
1
8
4
R
ib
o
so
m
a
l
P
ro
te
in
L
5
R
ib
o
so
m
a
l
P
ro
te
in
S
9
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4 0
1
2
A B C S1 S2 S3 S4
G
A
P
D
H
L
D
H
-A
P
o
ly
-
U
B
IQ
U
IT
IN
%
A
C
T
IN
E
2
a
Acute  Binge Chronic   S1   S2   S3   S4   
  Sensitization
SEMAPHORINS
H A C V H A C V
0
2
A B C S1 S2 S3 S4 0
2
4
6
A B C S1 S2 S3 S4 0
2
4
6
A B C S1 S2 S3 S4 -6
-4
-2
0
2
A B C S1 S2 S3 S4
0
2
A B C S1 S2 S3 S4 0
5
10
A B C S1 S2 S3 S4 0
4
8
A B C S1 S2 S3 S4 0
4
8
A B C S1 S2 S3 S4
0
5
10
A B C S1 S2 S3 S4 0
5
10
A B C S1 S2 S3 S4 0
5
10
A B C S1 S2 S3 S4 0
5
10
A B C S1 S2 S3 S4
-2
0
2
A B C S1 S2 S3 S4
-4
-2
0
2
A B C S1 S2 S3 S4
-8
-4
0 A B C S1 S2 S3 S4
0
5
10
A B C S1 S2 S3 S4
0
2
A B C S1 S2 S3 S4 0
2
4
A B C S1 S2 S3 S4 0
2
A B C S1 S2 S3 S4 0
5
10
A B C S1 S2 S3 S4
-9
-6
-3
0 A B C S1 S2 S3 S4
-8
-4
0 A B C S1 S2 S3 S4
0
2
4
A B C S1 S2 S3 S4 -10
-5
0 A B C S1 S2 S3 S4
S
e
m
a
4
A
S
e
m
a
4
B
S
e
m
a
4
C
S
e
m
a
4
D
S
e
m
a
4
F
S
e
m
a
4
G
0
5
10
A B C S1 S2 S3 S4 -2
0
2
A B C S1 S2 S3 S4
-6
-4
-2
0 A B C S1 S2 S3 S4
0
5
10
A B C S1 S2 S3 S4
0
2
A B C S1 S2 S3 S4 -4
-2
0 A B C S1 S2 S3 S4
0
2
4
A B C S1 S2 S3 S4 -9
-6
-3
0 A B C S1 S2 S3 S4
S
e
m
a
5
A
S
e
m
a
5
B
0
2
4
A B C S1 S2 S3 S4 -8
-6
-4
-2
0 A B C S1 S2 S3 S4
-6
-4
-2
0 A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4 0
2
4
6
8
10
A B C S1 S2 S3 S4 -2
-1
0
1
2
A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4
-6
-4
-2
0 A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4 -2
0
2
A B C S1 S2 S3 S4
0
2
4
6
8
A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4 -4
-2
0 A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4 -8
-6
-4
-2
0 A B C S1 S2 S3 S4
0
2
A B C S1 S2 S3 S4 -8
-6
-4
-2
0 A B C S1 S2 S3 S4
0
2
4
A B C S1 S2 S3 S4 0
2
4
6
A B C S1 S2 S3 S4
S
e
m
a
3
A
S
e
m
a
3
B
S
e
m
a
3
C
S
e
m
a
3
E
S
e
m
a
3
F
0
2
4
6
A B C S1 S2 S3 S4 -2
0
2
A B C S1 S2 S3 S4
-2
0
2
A B C S1 S2 S3 S4
0
2
4
A B C S1 S2 S3 S4
0
2
4
A B C S1 S2 S3 S4 0
2
4
6
A B C S1 S2 S3 S4 -2
0
2
A B C S1 S2 S3 S4
0
2
4
6
A B C S1 S2 S3 S4
-9
-6
-3
0 A B C S1 S2 S3 S4
-12
-9
-6
-3
0 A B C S1 S2 S3 S4
-9
-6
-3
0 A B C S1 S2 S3 S4
-9
-6
-3
0 A B C S1 S2 S3 S4
S
e
m
a
6
A
S
e
m
a
6
B
S
e
m
a
6
C
0 A B C S1 S2 S3 S4
2
-6
-4
-2
0 A B C S1 S2 S3 S4
-6
-4
-2
0 A B C S1 S2 S3 S4
-10
-5
0 A B C S1 S2 S3 S4
S
e
m
a
7
A
ht
tp
://
do
c.
re
ro
.c
h
Fig. 3 
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Table 1. Gene candidates and Oligonucleotides.
Gene candidates, species and Gene ID (NCBI) are listed. Oligonucleotides for 
the different candidates were designed and checked (“Materials and 
Methods“). Oligonucleotides synthesized with 5’-amino modification, were 
arrayed onto QMT Aldehyde Slides with an OmniGrid Accent™ Microarrayer. 
aRNA samples (from samples of cocaine-treated and of saline-treated tissues) 
were reverse-transcribed in the presence of Cy3-dCTP (samples from saline-
treated tissues) or Cy5-dCTP (samples from cocaine-treated tissues) and 
hybridized. See Material and Methods for details. 
Name SpeciesGene_Id
Sema3A  Rat X95286 GAAGAAGGATTCAGGCAATTACCTGTGTCACGCCGTGGAGCACGGTTTCATGCAAACTCTTCTTAAGGTG
Sema3B  Mouse X85990 CCAGCACCCTATGCTCTGGAGACTCTTCTCACTCTGTGCTGCTGGAGAAGAAGGTGTTGGGTGTGGAGAG
Sema3C  Mouse X85994 CAATGGAAATCTCATCCAAAAAGCAACAGTTGTACGTGAGCTCCAATGAGGGGGTTTCCCAAGTCTCTCT
Sema3E  Mouse Z80941 CTTAAGCGGTATGTCTCAGGGGACAAAACCGTGGTACAAGGAATTCTTGCAGCTGATTGGCTACAGCAAC
Sema3F  Mouse AF080090 TCAATTCCAATGCAAACAAGAATGCCGTAGAGTCTGTGCAGTACGGAGTGGCCGGCAGCGCAGCTTTCCT
Sema4A  Mouse X85991 GTTTGGACAGATTGTTATTATTGTCTCTGCCCTGGCTAGAATGGGGGCATAATCTGAGCCTTGTTCCCTT
Sema4B  Mouse X85992 CAAGAATTCCTCATACAAGGCCCGGTTTCTTGTGCCAGGTAAGCCATGTAAACAAGTCCAGATCCAACCA
Sema4C  Mouse S79463 ACTTTCCTGTCTCTATCACGTCTTCCCTTGGCCTGGGGTCCTCCTGGTTGAGTCTTTGGAGCTATGAAGG
Sema4D  Mouse U69535 CAAATGTTTCCAAAAGTCCAACCTAGCCCGGGTGGTATGGAAGTTCCAGAATGGCGAGTTGAAGGCCGCA
Sema4F  Rat AB002563 CTAACCTAGCAGCATTGATCGTTCATTGTAAAGTGGGGATATACCTACCTCAGGGTTGCTGCAAGGATCA
Sema4G  Mouse AF134918 AGATTTCCCTTCCCATTTATCGGTCCTCACTGAACTAGGACAAGTGGCCAACACTGCACTCAATGAGCCA
Sema5A  Mouse X97817 GCTCTTATACTTTGGGCTCGTTGTAAACTCGCTGCTCCTCAAACCGTGCTCCATGGCTGCCCCATATTTC
Sema5B  Mouse X978181 GTAGAACCACTTTGGTTTACCCTCTGCACTGGGCCAAGAACTTGCTGCCTAGCCAGTAAGGGTCCCATCT
Sema6A  Mouse AF030430 GGCTGCCACCCTGGAGTATAAGACCATCAAAGAGCACCTGAGTAGCGAGAGTTCACCCTATGTTCTGAAG
Sema6B  Rat AB000776 GAACCTACTTCTAAAGGGCTTGTGGGGGGTTTTGGGAGGGTGGAAGTGGGCAGACACCCCTGTAAATACA
Sema7A  Mouse AB017532 TATTTTTTCGAAATCTCACACTTGACTTCATGCAGTGATGCACCTGGCCTGAGAGCCCATCAGCCTGGCA
Sema6C  Rat AB000817 GCCTTCCCGGACTCCAAGAGTCTCCCGGGGTCCCCTCTCGCCTCGGTTTATTTATTGACTGTCTTTCCCC
EphA1  Mouse U18084 GGAATAGCTCTGCTGATCGGGATTTATGTCTTCCGTTCAAGGAGAGGCCAGAGACAGAGACAGCAGAGGC
EphA2  Mouse X78339 AGGTCAACACAGTGGGGATTCCTATCTGAGTCCATTGGGGCCGTGCCCAACAATACTTGAAGAGCCACAG
EphA3 RAT U69278 TGGACCAAAGCAATGTCGATATTGCTACGTTCCACACAACAGGTGATTGGCTTAACGGTATGAGGACAGC
EphA4  Mouse X65138 GGCCCATTCATGCTGCCTCTTCAATGGCCAGGACACCTGGTGGATTTTTATGACATAGGGGGGGTTAGAA
EphA5 Rat X78689 GTTTGAAGACACTGGTGAACGCGTCAAGCAGGGTATCTACTTTGTTGGCAGAACATGGATCTTTGGGGTC
EphA7 Rat U21954 GACCAGAGCACTCCCGACTTCACTGCCTTCTGTTCAGTGGGAGAGTGGTTGCAGGCTATTAAAATGGAGA
EphA8 Rat X59290 GGTACTCCTCCCTTGGCATGGTGCTTCACATGAACGCCCAGGATGTTCGTGCCCTCGGCATCACCCTCAT
EphB1 Rat X13411 TTTCTCGGCCATGGAAGTGTGTAGAAGCCGTGGGAAACCAAACGCGTAATGATTGACGATAAAGACAGAG
EphB2  Mouse L25890 TTTGCCAACGCCGGCTTCACCTCTTTCGACGTTGTATCTCAGATGATGATGGAGGACATTCTCCGCGTTG
EphB3  Mouse Z49086 CCCAGGAAGTGTGCCCCAAACCTCTTCATATTGAAGATGGATTAGAAGAGGGGGTGATGTCCCCTCCCCA
EphB4  Mouse Z49085 GACAGTTCCCCGGAATTCCGGCAAGGATGCGCCGCTATATTAAGAATCCTCGAATTGTGCTATTGGATTC
EphB6  Mouse L77867 TCCCCAGGCCTGGCTTTCAGCCATTGGACTAGAGTGCTACCAGGACAACTTCTCCAAGTTTGGTCTTTCC
 Ephrin A1  Rat D38056 TGCTGCAAACTCAGTGAAGGTATTTGCTTGCCCTGGCTTACGGATTGGCACGGGACTAAGGGGCAGGGTT
EphrinA2  Mouse U14941 ACTCGCTTTCACCAGGCCACCAGGGCCATCCAGTGTTGTTTAATTACAGTCGGAAAGACTTAAGGTTTTT
EphrinA3  Mouse U90666 TGGACATTATTTGTCCGCACTACAACAGCTCAGGGCCTGGCGGCGGGGCGGACAGGTACGTGCTGTACAT
EphrinA4  Mouse U90663 TCCAGCGCTGGAATTGCTCGATGCCTTTTGCCCCTTTCAGCCCTGTTCGATTCTCAGAAAAGATTCAGCG
EphrinA5 RAT U69279 CAAAGGGTTCAAGAGATGGGAATGTAACCGGCCTCACTCTCCAAACGGACCGCTGAAGTTCTCGGAGAAA
EphrinB1 Rat U07560 GCTCTCTTAACCCTAAGTTCCTAAGTGGGAAGGGCTTGGTGATCTACCCGAAGATTGGAGATAAGCTGGA
EphrinB2  Mouse U16819 AGAGGTACTGGAAATAAAAAGCGCAGCGCAGAGCTGTGGGAGAGTCCGTCTGCTTTGGGAGATGTTTTAA
EphrinB3  Mouse AF025288 TCCTCTCCTAGTTATGAGTTCTACAAACTGTACCTGGTAGAGGGTGCCCAGGGTCGGCGTTGTGAGGCAC
Neuropilin1  Mouse D50086 CTGTGGTGGATTCTTCTCGGAAACTGCAAAATCCAAGATGCTGGCACTAGGCGTTATTCAGTGGGCCCTT
Neuropilin2 Rat AF016297 ACAAGGTCAAGATCAATCACCAGAAGTGCTGCTCGGAGGCATGACCGATTGTGTCTGAATCGCTTCTGGC
Oligo Sequence
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Table 2. Primer sets designed for quantitative RT-PCR.
See Material and Methods.
Forward Primer Reverse Primer 
GAPDH ATGACTCTACCCACGGCAAG CATACTCAGCACCAGCATCAC 
E-Actin AGCCATGTACGTAGCCATCC CTCTCAGCTGTGGTGGTGAA 
HSP-70 CCAGCTACGTGGCCTTCAC GCTTCATGTCCGACTGCAC 
GP62 TCTCAGCTCCAGCGACAAC GCAGTAGTAGTGGTGGTGGTAG
LDHA ACTCTAACACGCTGGCTGAG CACCCGCACCCTGATACAG 
Sema3A GGCTCCTGCTTCGTAGTCTG GCCATCTCCATCGTCATCTT 
Sema4F TTATGCTTGCGAGTGTCAGG GAGGAGAGTGAGGGATGCTG 
Sema7A GCTCCATTGCAGAAGGTTTC GTTGAGCCTCACGGAGGTAG 
Neuropilin1 GGCACCAAGGAGACCACTG CATCCACAGCAATTCCACCAAG
EphA3 GCTGGCAGAAAGACAGGAAC ACCGTTAAGCCAATCACCTG
Sema6B GCTTATGCAGAATGGCTGGAC GCGTGTGGGTGTGTTGTG
Sema6C TCAGCCTCCCGATCCATCC ACAAGCACAGGACACCAAGAG
Sema5A GGACCCCTGTCAACATCTCTG CCTCTGTCTTCCTACTTCCAGC
EphA5 GCAGACCTGGGTTCTTCAAAG CATTGTGGGCGGATCAGATTC
EphB1 CCAGTTTGACCATCCCAACATC GTCTAAAGCGCCATTCTCCATG
EphrinA1 CCTCTCTTGGGTCTGTGCTG TCCTCGTAATGTGGGCAGATG 
EphrinB1 CAAGCTCCGCAAACGACATC TGTTCTCTGTAGTCCGTAAGGG
EphB2 AGAATGGTGCCATCTTCCAG CCTTGAAGGTTCCTGATGGA
EphrinB2 AGGAATCACGGTCCAACAAG GTCTCCTGCGGTACTTGAGC 
EphrinA5 GCTGCTCTTTCTGGTGCTCT GGGCAGAAAACATCCAGGTA 
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Table 3. Statistical Analysis of Genes modified by Cocaine Treatments and confirmed by qRT-PCR.
Statistical significance of the genes candidates modified by cocaine from microarray and confirmed by 
qRT-PCR (see Fig 4) was evaluated by the two-tailed Student’s test (see Methods). -P0.05; *P<0.05; 
**P<0.01; ***P<0.005. 
A B C S1 S2 S3 S4 A B C S1 S2 S3 S4 A B C S1 S2 S3 S4 A B C S1 S2 S3 S4
Sema3A - - - - - - - - - - * - - - * - - - - - - - - - - - - -
Sema3B - - ** - - - - - - *** - - - - - - - - - - - - - - - - - -
Sema3C - - - - - - * - - - - - - - - - - - - - - - - ** - - - ***
Sema3E * ** *** * * ** *** ** * * * * * * ** * ** * ** ** *** *** * * ** ** * ***
Sema3F - - - - - - - *** - - - - - * - - - - - - ** - - - - - - ***
Sema4A - - - - - - - ** - - - - - - - - - - - - - * - - - - - -
Sema4B - - - - - - - - - *** - - - - - - - - - - - - - * - - - -
Sema4C *** - - - - - - - - *** - - - - - - *** - - - - - - - - - - -
Sema4D - - - - - - - - - - - - - - *** - - - - - - * - - - - - -
Sema4F - - - - - - * - - - - - - - - - - - - - - - - - - - - ***
Sema4G *** - - - - - - - - - - - - * * - - - - - ** *** - - - - - ***
Sema5A - ** *** - - - - - - - - - - - - - * - - - - - *** ** - - - ***
Sema5B - - - - - - - * - - * - - - * - - - - - - *** - - ** - - -
Sema6C - - - ** - - - - - - *** - - - - - - *** - - - - - - *** - - -
Sema7A - - - - - - - *** - - - - - - - - - - - - - *** - - - - - -
NP-1 * * ** - * ** ** ** * ** - * ** ** ** * ** - ** ** ** * ** ** - * ** ***
A B C S1 S2 S3 S4 A B C S1 S2 S3 S4 A B C S1 S2 S3 S4 A B C S1 S2 S3 S4
EphA1 - - - - - - - - - - - - - - *** - - - - - - - - - - - - -
EphA3 - - - - - - - * - - - - - - *** - - - ** - - - - - - - - -
EphA5 - - - - - * * - - - - - - - - - - * * * * - - - - - - *
EphA8 * * * - - * * * * - - * * * * - - - * - * - - - * - * *
EphB1 - - ** - - - ** - - ** - - - ** - - * - - - * - - * - - - ***
EphB2 - - ** - - - - - - ** - - - - - - * - - - - - - * - - - ***
EphB3 - - * - - - - - - ** - - - - - - - - - - - - - - - - - -
EphB4 - - *** - - - - - - *** - - - - - - - - - - - - - - - - - -
EphB6 - - - - - - - - - ** - - - - - - - - - - - - - - - - - -
EphrinA1 - - - - - - - - - - - - - - *** - - - - - - * - - - - - -
EphrinA3 - - - - - - - - - - - - - - *** - - - - - - ** - - - - - -
EphrinA5 - - - - - - - - - - - * - ** - - - - - - - - - - - - - *
Nucleus AccumbensHi
EphrinB2 - - - - - - *** - - - - - - ** - - - - - - ** - - - - - - ***
EphrinB3 - - - - - - *** - - - - - - * - - - - - - * - - - - - - *
ppocampus Caudate Putamen Ventral Tegmentum Area
Hippocampus Nucleus Accumbens Caudate Putamen Ventral Tegmentum Area
